Open AccessModern approaches to the treatment of type 2 diabetes mellitus and its complications
Author(s) -
А С Аметов,
Е В Доскина
Publication year - 2012
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl201258361-64
Subject(s) - diabetes mellitus , pathogenesis , medicine , adhesion , type 2 diabetes mellitus , disease , endocrinology , gastroenterology , chemistry , organic chemistry
According to the International Diabetes Federation, there are over 366 mln subjects suffering diabetes mellitus (DM) in the world. This figure is expected to reach 552 mln by 2030. The patients are treated with preparations acting on different components of DM pathogenesis on the one hand and with medicines facilitating prophylaxis of the disease on the other hand. Diabeton MB decreases the mean HbA1c level of 7-8% by 0.9%. Also, it causes reduction of the initial HbA1c levels of 8-9% and 10% by 1.7% (2.6---??) and 4.2% respectively. Diabeton MB produces a number of other effects besides the hypoglycemic activity; specifically, it reduces the intensity of LDLP oxydation, platelet adhesion and aggregation, adhesion of monocytes, etc.